Google
FOLD — AMICUS THERAPEUTICS INC (Healthcare >> Biotechnology)
FOLD FAQ
What is FOLD's P/E ratio?
AMICUS THERAPEUTICS INC (FOLD) currently trades at a P/E ratio of 239.79.
What is FOLD's ROE?
AMICUS THERAPEUTICS INC reports a Return on Equity (ROE) of -9.89%.
What is FOLD's dividend yield?
AMICUS THERAPEUTICS INC offers a dividend yield of 0.00%.
What is FOLD's Deepscope Quality Score?
Deepscope rates FOLD's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy FOLD?
Deepscope's AI Timing Score for FOLD is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does FOLD belong to?
AMICUS THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 14.49
Price
0.03
(0.21%)
Day Change
|
|
|---|
FOLD, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
41% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 14.49 |
| PBV / Sector |
16.61 / 4.58
|
| Earning Per Share | -0.09 |
| PE / Sector |
239.79 / 17.10
|
| PEG or PE/Growth / Sector |
-4.73 / 0.52
|
| Average 1M Daily Value |
37.07 M
GREAT
|
| Average 1W Daily Value |
36.23 M
GREAT
|
| Timing Factors |
|
100% |
| Financial Health |
|
39% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-05 09:12:36 |
| Symbol | FOLD |
| Name | AMICUS THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 314.00 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 4,555.01 / 8,655.90 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 47 Hulfish Street, Princeton, NJ, United States, 08542
Phone: 609 662 2000
Website: https://amicusrx.com
Employees: 511
Sector: Healthcare >> Biotechnology
Description: Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. As of April 27, 2026, Amicus Therapeutics, Inc. operates as a subsidiary of BioMarin Pharmaceutical Inc.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
